P. F. VON VOIGTLANDER

Author

W.E. Upjohn Institute for Employment Research

Also Known As

P F Von Voigtlander, P. F. VON VOIGTLANDER, P. F. Von Voigtlander, P.F. VON VOIGTLANDER, P.F. Von Voigtlander, P.F. von Voigtlander, P.F.Von Voigtlander, Philip F Von Voigtlander, Philip F. Von Voigtlander, Philip F. von Voigtlander

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

W.E. Upjohn Institute for Employment Research Michigan State University CNS Research (United States)

About

P. F. VON VOIGTLANDER is an author at W.E. Upjohn Institute for Employment Research specializing in medicine, pharmacology, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	1.6K
2	Social Sciences	7	7	456
3	Health Sciences	3	3	214
4	Natural Sciences	3	3	615
5	Anesthesia	1	1	139

P. F. VON VOIGTLANDER

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
[3H]U-69593 a highly selective ligand for the opioid κ receptor Robert A. Lahti, Mary M. Mickelson, John M. McCall, European Journal of Pharmacology Molecular PharmacologyDrug TargetBiochemistryMedicineNatural Sciences	1985	445
INVOLVEMENT OF NIGRO-STRIATAL NEURONS IN THE IN VIVO RELEASE OF DOPAMINE BY AMPHET-AMINE, AMANTADINE AND TYRAMINE P. F. VON VOIGTLANDER, Kenneth E. Moore Journal of Pharmacology and Experimental Therapeutics	1973	232
Turning behavior of mice with unilateral 6-hydroxydopamine lesions in the striatum: Effects of apomorphine, l-DOPA, amantadine, amphetamine and other psychomotor stimulants P. F. VON VOIGTLANDER, Kenneth E. Moore Neuropharmacology NeuropsychologyPsychiatryBehavioral NeuroscienceNeuroanatomyAddiction	1973	206
Benzeneacetamide amines: structurally novel non-m.mu. opioids Jacob Szmuszkovicz, P. F. VON VOIGTLANDER Journal of Medicinal Chemistry Molecular PharmacologyMedicinal ChemistryPharmaceutical ScienceDonut IconMedicine	1982	155
U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia. Edward D. Hall, J. Mark Braughler, Patricia A. Yonkers, Journal of Pharmacology and Experimental Therapeutics	1991	152
Dopamine: Release from the Brain in vivo by Amantadine P. F. VON VOIGTLANDER, Kenneth E. Moore Science NeurotransmitterSocial SciencesNeurochemistryElectrical StimulationNeuropharmacology	1971	139
Neuroprotective effects of the dopamine D 2 /D 3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons Edward D. Hall, Paula K. Andrus, Jo A. Oostveen, Brain Research Agonist PramipexoleDopamine D 2MedicineNigrostriatal NeuronsNeuropharmacology	1996	132
Hydroxyl radical production and lipid peroxidation paralles selective post‐ischemic vulnerability in gerbil brain Edward D. Hall, Paula K. Andrus, John S. Althaus, Journal of Neuroscience Research	1993	131
U-50,488, a selective kappa opioid agonist: Comparison to other reputed kappa agonists P. F. VON VOIGTLANDER, Richard A. Lewis Progress in Neuro-Psychopharmacology and Biological Psychiatry Opioid EpidemicSubstance AbusePsychoactive DrugFunctional SelectivityAddiction	1982	104
Interactions between clonidine and antidepressant drugs: A method for identifying antidepressant-like agents P. F. VON VOIGTLANDER, Herman J. Triezenberg, Elizabeth G. Losey Neuropharmacology Drug InteractionsAntidepressant DrugsPsychoactive DrugAntidepressant-like AgentsPsychiatry	1978	92

Page 1